Anabolic Steroids

The single largest determinant of AAS detection is which specific agent and ester were used. Oral oxandrolone has a plasma half-life of roughly 9 hours and may be undetectable within a week of discontinuation. Oral stanozolol (Winstrol) has a half-life of approximately 9 hours but produces metabolites with vastly longer detection windows. Long-chain injectable nandrolone decanoate releases drug slowly from intramuscular depot over many weeks — the apparent elimination half-life is dominated by depot release rather than drug clearance — and produces detectable nandrolone metabolites in urine for 6–12 months or longer after a single injection. Testosterone esters span a wide range: propionate (effective half-life ~2 days) clears far faster than enanthate or cypionate (~5–10 days) or undecanoate (multi-week depot). Trenbolone esters, boldenone undecylenate, and methenolone enanthate each have their own characteristic depot pharmacokinetics. Any program designing an AAS detection strategy must consider which agents are plausibly present in the target population.

Endogenous testosterone production complicates testing for exogenous testosterone specifically. The traditional WADA screening approach uses the urinary testosterone-to-epitestosterone (T/E) ratio: a ratio above 4:1 triggers further investigation, because exogenous testosterone administration suppresses epitestosterone production and elevates T relative to E. Some individuals have naturally elevated T/E ratios; some have suppressed epitestosterone for non-doping reasons; some sophisticated doping protocols deliberately co-administer epitestosterone to manipulate the ratio. Isotope ratio mass spectrometry (IRMS) resolves the question by measuring the carbon-13 isotope signature of urinary testosterone, which differs between endogenous testosterone (synthesized from cholesterol via the human gonad and adrenal) and synthetic pharmaceutical testosterone derived from soy and yam plant precursors. UGT2B17 polymorphisms affect baseline T/E ratio — individuals with the deletion polymorphism have constitutively low T/E ratios and can carry significant exogenous testosterone loads while still falling below the 4:1 threshold, which is part of why IRMS confirmation is required rather than T/E alone.

Other AAS produce metabolite profiles distinguishable from endogenous steroid metabolism by standard GC-MS or LC-MS/MS, without requiring IRMS confirmation. Nandrolone (19-nortestosterone) produces 19-norandrosterone and 19-noretiocholanolone urinary metabolites that are not produced by endogenous testosterone metabolism, although trace amounts can occur from dietary boar meat consumption and from endogenous production in pregnancy. Stanozolol, oxandrolone, methandienone, trenbolone, and most other synthetic agents have characteristic metabolite signatures. Hepatic 17-alpha-alkylated oral agents (oxandrolone, stanozolol, methandienone, oxymetholone) resist first-pass hepatic metabolism and produce hepatotoxicity profiles that are independent of detection but operationally relevant to the clinical population being tested. Drug-drug interactions that modulate hepatic CYP3A4 or 5-alpha-reductase can shift metabolite ratios.

Pre-analytical factors — sample collection, transport, chain of custody, storage conditions — matter substantially in AAS testing because the medical-legal and competitive stakes are typically high. WADA and USADA protocols specify witnessed collection, A-sample and B-sample handling, and documented chain of custody, with the B-sample held in long-term storage to support athlete-requested re-analysis and to support retrospective re-testing as analytical methods improve. Clinical laboratories operating outside the anti-doping framework should still follow rigorous specimen handling. Specimen integrity testing — creatinine, specific gravity, pH, and oxidant adulterant panels — accompanies AAS screens just as it does drug-of-abuse screens, and adulterated or substituted specimens are handled per program protocol; collectors trained to verify specimen temperature within four minutes of collection (90–100°F) catch the most common substitution attempts at the point of collection.

There is no single industry urinary screening cutoff for AAS analogous to the SAMHSA 50 ng/mL THC cutoff or the 500 ng/mL amphetamines cutoff, and AAS sit entirely outside the SAMHSA Mandatory Guidelines and DOT-regulated frameworks. WADA publishes a Technical Document on Decision Limits for the Confirmatory Quantification of Threshold Substances that specifies thresholds for each individual analyte. The urinary T/E ratio screening threshold is 4:1, with mandatory IRMS follow-up above that threshold. Nandrolone metabolites have a threshold of 2 ng/mL urinary 19-norandrosterone for males and 2 ng/mL for females (with specific provisions for pregnancy and dietary exposure). Stanozolol metabolite thresholds are in the low ng/mL range. Threshold values are updated periodically by WADA as analytical sensitivity improves and as new doping agents emerge.

Anti-doping laboratories operating under WADA accreditation follow the International Standard for Laboratories and report quantitative confirmation results for each analyte detected. Results above the threshold are reported as Adverse Analytical Findings and trigger results-management procedures under the World Anti-Doping Code. Clinical endocrinology laboratories evaluating patients for suspected exogenous testosterone use apply similar analytical techniques (LC-MS/MS, IRMS) but report results in a clinical rather than anti-doping framework. The immunoassay-to-mass-spectrometry confirmation gap that organizes routine drug-of-abuse screening does not apply in the same way to AAS testing — the entire AAS workflow runs on mass-spectrometric methods from the initial testing procedure forward, and there is no presumptive CLIA-waived screen that precedes laboratory analysis.

Programs without an existing relationship to a WADA-accredited or equivalent specialty laboratory should engage one directly before designing an AAS testing protocol, ideally before any specimens are collected, because collection, transport, and storage protocols differ from routine drug-of-abuse procedures. Routine clinical reference laboratories generally do not offer the full WADA-style analyte panel; specialty endocrine and anti-doping laboratories do. Medical Review Officer review remains relevant when the program is investigating possible therapeutic testosterone replacement (TRT) prescribed for diagnosed hypogonadism, since legitimate FDA-approved testosterone use will produce positive IRMS results indistinguishable from non-medical use without prescription documentation. Magenta does not provide AAS testing devices and cannot fulfill AAS screening needs from its CLIA-waived point-of-care catalog.

AAS detection is performed by specialty laboratories using analytical-instrument methods that are fundamentally different from the lateral-flow competitive-immunoassay technology in Magenta's point-of-care devices. The standard workflow at a WADA-accredited laboratory begins with sample preparation (hydrolysis to release conjugated metabolites, liquid-liquid or solid-phase extraction, derivatization as required for GC methods), followed by initial testing procedure by GC-MS, LC-MS/MS, or GC-combustion-IRMS depending on the analyte class. The initial testing procedure identifies presumptive positives across a broad panel of AAS analytes. Confirmation testing by a second analytical method (typically LC-MS/MS or GC-MS/MS) at quantitative thresholds defined in WADA Technical Documents establishes the Adverse Analytical Finding. Chain-of-custody documentation accompanies the specimen from witnessed collection through laboratory analysis and results management.

The testosterone-to-epitestosterone (T/E) ratio screening test is the historical foundation of urinary testosterone detection. A T/E ratio above 4:1 triggers mandatory follow-up by isotope ratio mass spectrometry. IRMS measures the carbon-13 to carbon-12 isotope ratio of testosterone and its metabolites; pharmaceutical testosterone synthesized from plant precursors shows a different isotope signature than endogenous testosterone synthesized by the human gonad and adrenal. A depleted carbon-13 signal in the testosterone or testosterone metabolite fraction is diagnostic of exogenous testosterone exposure, independent of the T/E ratio. IRMS is the gold-standard test for exogenous testosterone and is the analytical answer to the well-known false-positive and false-negative limitations of T/E-ratio screening alone.

Non-testosterone AAS — nandrolone, stanozolol, oxandrolone, methandienone, trenbolone, boldenone, methenolone, and many others — produce characteristic metabolite signatures detectable by GC-MS or LC-MS/MS at the threshold values published in WADA Technical Documents. The laboratory reports each analyte separately with quantitative confirmation. Some metabolites are extraordinarily long-lived: stanozolol metabolites have produced positives more than a year after the last documented exposure, and nandrolone metabolites can remain detectable for 6–18 months following a single intramuscular nandrolone decanoate injection. Long-term metabolite detection is the basis for WADA's extended sample-retention policies, which support retrospective re-analysis of stored B-samples as analytical methods improve and as additional designer-steroid metabolites are characterized.

The WADA Athlete Biological Passport adds a longitudinal-monitoring layer that compares an athlete's current steroidal profile to the athlete's own historical baseline rather than to a population-derived threshold. Sustained shifts in serum or urinary steroid markers — testosterone, epitestosterone, androsterone, etiocholanolone, 5α-androstane-3α,17β-diol, 5β-androstane-3α,17β-diol, and others — can indicate exogenous AAS administration even when no single sample exceeds a fixed threshold. The Steroidal Module of the Athlete Biological Passport is a longitudinal-monitoring tool used in elite anti-doping programs and represents a different statistical framework than the population-threshold approach used in routine drug-of-abuse screening.

Programs operating outside the WADA framework — clinical endocrinology evaluations, certain corrections and law-enforcement populations, some specialty fitness-industry contexts, and academic research — should engage a specialty laboratory experienced with AAS analysis. Magenta does not offer point-of-care or laboratory AAS testing. Programs that need to screen for AAS as part of a broader drug-of-abuse program should plan to send specimens to a specialty laboratory in parallel with the routine point-of-care or laboratory panel, with separate collection, separate chain of custody, and separate result-management workflow. Observed-versus-unobserved collection follows the rules of the operative framework: WADA collection is witnessed by trained doping control officers; clinical and corrections AAS collection follows the program's local protocol, which typically aligns with reasonable-suspicion or fitness-for-duty observation rules.